Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's DiseasePRNewsWire • 02/08/23
Does Annovis Bio, Inc. (ANVS) Have the Potential to Rally 178.45% as Wall Street Analysts Expect?Zacks Investment Research • 02/01/23
Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental IllnessesPRNewsWire • 02/01/23
ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASEPRNewsWire • 01/25/23
Can Annovis Bio, Inc. (ANVS) Climb 251% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 12/02/22
Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 239%: Here's is How to TradeZacks Investment Research • 11/16/22
Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's DiseasePRNewsWire • 10/11/22
Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's DiseasePRNewsWire • 10/06/22
Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A LookSeeking Alpha • 10/06/22
Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion DiseasesPRNewsWire • 09/13/22
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's DiseasePRNewsWire • 08/24/22
Annovis Bio to Participate on Alzheimer's Association International Conference PanelPRNewsWire • 08/01/22